Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 11 3 2012 09 15 236 240 EN Fakhrozaman Pezeshkpoor Research Center for Skin Diseases and Cutaneous Leishmaniasis, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Reza Farid Hosseini Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Houshang Rafatpanah Inflammation Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Behzad Shakerian Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Farahzad Jabbari Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Mohammad Reza Zandkarimi Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Hadis Yousefzadeh PhD Student of Immunology, Student Research Assembly of MUMS, Mashhad, Iran Homa Sadri Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Abdolazim Bahrami Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Mohammad Ali Zamani Inflammation Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2015 10 16 Chronic Idiopathic Urticaria is defined as recurrent hives occurring for at least 6 weeks. In  the  majority of  cases, there  is no  identifiable underlying etiology despite  extensive evaluation. A subset of these patients is classified as having autoimmune urticaria defined by the presence of a functional IgG antibody to the α subunit of the high-affinity IgE receptor (FceRIa) or to IgE. The aim of this study was to evaluate the effects of the drug atorvastatin in patients with chronic urticaria compared to the placebo. In this single-blind study, 50 patients suffering from chronic urticaria (15-45 years old) were selected and divided into two groups by simple randomization method. The first group was treated with atorvastatin and antihistamines and the second group (control group) was treated with placebo and antihistamines for 3 months. Urticaria severity was measured by score index, before and after the treatment course: ASST (Autologous serum skin test) was performed for all patients and sera were collected to measure cytokines. In cases, IL-5 decreased and IL-10 increased after treatment compared to the time point before  treatment  (p<0.05). All patients with severe utricaria according our  scoring, had positive ASST. The patients with severe urticaria identified by urticaria score and ASST positivity had chronic idiopathic urticaria. By prescribing the Atorvastatin plus antihistamines in severe and resistant forms of urticaria, the use of more toxic medications like cytotoxic drugs may be avoided. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/557 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/557/485